Shareholder alert: robbins llp informs investors of class action against fate therapeutics, inc. (fate)

San diego--( business wire )--the class: robbins llp informs shareholders that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired shares fate therapeutics, inc. (nasdaq: fate) common stock between april 2, 2020 and january 5, 2023, for violations of the securities exchange act of 1934. fate is a clinical-stage biopharmaceutical company that develops programmed cellular immunotherapies to treat cancer and immune disorders.
FATE Ratings Summary
FATE Quant Ranking